Citations

Clear

4207 citation(s) found for "Chen, Yu".

Importance of the vasculature in cyst formation after spinal cord injury
Rooney, Gemma E., Endo, Toshiki , Ameenuddin, Syed, Chen, Bingkun , Vaishya, Sandeep , Gross, LouAnn, Schiefer, Terry K., Currier, Bradford L. , Spinner, Robert J. , Yaszemski, Michael J. , Windebank, Anthony J.

Mayo Clinic

Journal of Neurosurgery: Spine | February 23, 2011 | Volume: 11 | Issue: 4 | Pages: 432-437

10.3171/2009.4.spine08784 | PMID 19929340 Get It

Object Glial scar and cystic formation greatly contribute to the inhibition of axonal regeneration after spinal cord injury (SCI). Attempts to promote axonal regeneration are extremely challenging in this type of hostile environment. The objective of this study was to examine the surgical methods that may be used to assess the factors that influence the level of scar and cystic formation in SCI. Methods In the first part of this study, a complete transection was performed at vertebral level T9–10 in adult female Sprague-Dawley rats. The dura mater was either left open (control group) or was closed using sutures or hyaluronic acid. In the second part of the study, complete or subpial transection was performed, with the same dural closure technique applied to both groups. Histological analysis of longitudinal sections of the spinal cord was performed, and the percentage of scar and cyst formation was determined. Results Dural closure using sutures resulted in significantly less glial scar formation (p = 0.0248), while incorporation of the subpial transection surgical technique was then shown to significantly decrease cyst formation (p < 0.0001). Conclusions In this study, the authors demonstrated the importance of the vasculature in cyst formation after spinal cord trauma and confirmed the importance of dural closure in reducing glial scar formation.
Assessment of Chronic Hepatitis and Fibrosis: Comparison of MR Elastography and Diffusion-Weighted Imaging
Wang, Yi , Ganger, Daniel , Levitsky, Josh , Sternick, Laura A., McCarthy, Robert J. , Chen, Zongming E., Fasanati, Charles, Bolster, Bradley D. , Shah, Saurabh , Zuehlsdorff, Sven , Omary, Reed A. , Miller, Frank H. , Ehman, Richard L. , Miller, Frank H

Mayo Clinic

American Journal of Roentgenology | February 22, 2011 | Volume: 196 | Issue: 3 | Pages: 553-561

10.2214/ajr.10.4580 | PMID 21343496 Get It

Label-Free Proteomic Identification of Endogenous, Insulin-Stimulated Interaction Partners of Insulin Receptor Substrate-1
Geetha, Thangiah , Langlais, Paul R. , Luo, Moulun , Mapes, Rebekka, Lefort, Natalie , Mandarino, Lawrence J. , Yi, Zhengping , Chen, Shu‐Chuan , Geetha, Thangiah

Mayo Clinic

Journal of the American Society for Mass Spectrometry | January 28, 2011 | Volume: 22 | Issue: 3 | Pages: 457-466

10.1007/s13361-010-0051-2 | PMID 21472564 Get It

C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
Perez, Edith A. , Jenkins, Robert B. , Dueck, Amylou C. , Wiktor, Anne E., Bedroske, Patrick P., Anderson, S. Keith , Ketterling, Rhett P. , Sukov, William R. , Kanehira, Kazunori, Chen, Beiyun, Geiger, Xochiquetzal J., Andorfer, Cathy, McCullough, Ann E. , Davidson, Nancy E. , Martino, Silvana, Kutteh, Leila A., Harris, Lyndsay N. , Lingle, Wilma L., Reinholz, Monica M., Sledge, George W. , Kaufman, Peter A. , Gralow, Julie R. , Ingle, James N. , Dueck, A. C. , Ketterling, Rhett P

Mayo Clinic

Journal of Clinical Oncology | January 19, 2011 | Volume: 29 | Issue: 6 | Pages: 651-659

10.1200/jco.2010.30.2125 | PMID 21245420 Get It

Purpose Findings from the human epidermal growth factor receptor 2 (HER2) –positive National Surgical Adjuvant Breast and Bowel Project (NSABP) B31 trial suggested that MYC/HER2 coamplification (> 5.0 copies/nucleus) was associated with additional benefit from adjuvant trastuzumab in patients with early-stage breast cancer. To further explore this relationship, we investigated associations between MYC amplification and disease-free survival (DFS) in a similar adjuvant trastuzumab HER2-positive breast cancer trial—North Central Cancer Treatment Group (NCCTG) N9831. Patients and Methods This analysis included 799 patients randomly assigned to receive chemotherapy alone or with concurrent trastuzumab on N9831. Fluorescence in situ hybridization (FISH) was performed by using a dual-probe mixture for MYC and centromere 8 (MYC:CEP8) on tissue microarrays. MYC amplification was prespecified as MYC:CEP8 ratio > 2.2 or average MYC copies/nucleus > 5.0. Exploratory variables included polysomy 8. Results In comparing DFS (median follow-up, 4.0 years) between treatments, patients with MYC:CEP8 ratio ≤ 2.2 (n = 618; 77%) and > 2.2 (n = 181; 23%) had hazard ratios (HRs) of 0.46 (P < .001) and 0.67 (P = .33), respectively (interaction P = .38). Patients with MYC copies/nucleus ≤ 5.0 (n = 534; 67%) and > 5.0 (n = 265; 33%) had HRs of 0.52 (P = .002) and 0.48 (P = .02), respectively (interaction P = .94). Patients with MYC:CEP8 ratio < 1.3 with normal chromosome 8 copy number (n = 141; 18%) and ≥ 1.3 or < 1.3 with polysomy 8 (n = 658; 82%) had HRs of 0.66 (P = .28) and 0.44 (P < .001), respectively (interaction P = .23). Patients with MYC copies/nucleus < 2.5 (n = 130; 16%) and ≥ 2.5 (n = 669; 84%) had HRs of 1.07 (P = .87) and 0.42 (P < .001), respectively (interaction P = .05). Conclusion We did not confirm the B31 association between MYC amplification and additional trastuzumab benefit. Exploratory analyses revealed potential associations between alternative MYC/chromosome 8 copy number alterations and differential benefit of adjuvant trastuzumab.
MS cortical lesion or not?
Chen, Jacqueline T., Pirko, Istvan

Mayo Clinic

Neurology | January 6, 2011 | Volume: 76 | Issue: 5 | Pages: 412-413

10.1212/wnl.0b013e31820a0d6e | PMID 21209372 Get It

Sustained Delivery of Dibutyryl Cyclic Adenosine Monophosphate to the Transected Spinal Cord Via Oligo [(Polyethylene Glycol) Fumarate] Hydrogels
Rooney, Gemma E., Madigan, Nicolas N. , Gross, LouAnn, Chen, BingKun, Vallejo‐Giraldo, Catalina , Seo, Seungmae , Nesbitt, Jarred J., Dadsetan, Mahrokh, Yaszemski, Michael J. , Windebank, Anthony J. , Knight, Andrew Michael

Mayo Clinic

Tissue Engineering Part A | January 4, 2011 | Volume: 17 | Issue: 9-10 | Pages: 1287-1302

10.1089/ten.tea.2010.0396 | PMID 21198413 Get It

Do the ASCO/CAP 2007 HER2 Testing Guidelines Improve Prediction of Benefit to Adjuvant Trastuzumab?: Data from North Central Cancer Treatment Group N9831 Adjuvant Trial.
Perez, Edith A. , Reinholz, Monica M., Tenner, Kathleen , Davidson, Nancy E. , Harris, Lyndsay N. , Kutteh, Leila A., Jenkins, Robert B. , Chen, B., Dueck, Amylou C. , Gralow, Julie R.

Mayo Clinic

Cancer Research | December 30, 2010 | Volume: 69 | Issue: 24_Supplement | Pages: 701-701

10.1158/0008-5472.sabcs-09-701 Get It

Abstract Background: In 2007, the American Society of Clinical Oncology and College of American Pathologists (ASCO/CAP) recommended new guidelines to define HER2 positivity by immunohistochemistry (3+ IHC: uniform intense membrane staining of &gt;30% of invasive tumor cells) or fluorescent in situ hybridization (FISH+: HER2/CEP17 ratio &gt;2.2). The original criteria used for enrollment in the pivotal N9831 trial conducted from 2000-2005 were IHC&gt;10% (3+) or FISH ≥2.0.Purpose: To investigate the impact of the ASCO/CAP guidelines on patient (pt) eligibility and disease free survival (DFS) compared to the originally used FDA-approved definitions.Patients/Methods: This analysis included 2268 patients from the HER2+ N9831 adjuvant trastuzumab phase III trial. IHC was centrally performed at the Mayo Clinic using the DAKO HercepTest™ and was re-analyzed to determine the percent of tumor cells with 0, 1+, 2+, and 3+ staining intensities. DFS was compared between pts randomized to standard chemotherapy +/- concurrent trastuzumab (Arms A and C of the trial) within IHC/FISH subgroups using Cox proportional hazards regression stratified by hormone receptor and nodal status.Results: Based on 2268 pts, 83 pts (3.7%) were 3+ by FDA-approved guidelines but not 3+ by the ASCO/CAP guidelines. Among these pts, 77% (64/83) were FISH amplified centrally by ASCO/CAP guidelines. Only 1.5% (34/2268) of pts eligible under FDA-approved definitions from N9831 in this sample set would not meet the ASCO/CAP guidelines. In 1441 patients randomized to standard chemotherapy +/- concurrent trastuzumab, the exploratory DFS hazard ratio (HR) associated with trastuzumab in IHC/FISH subgroups were as follows: ASCO/CAP HER2+ HR=0.59 (95% CI: 0.47-0.75; p&lt;0.001); FDA-approved HER2+ HR=0.60 (95% CI: 0.47-0.75; p&lt;0.001); ASCO/CAP HER2 normal(not positive) HR=0.74 (95% CI: 0.35-1.57; p=0.43); and FDA-approved HER2 normal HR=0.53 (95% CI: 0.22-1.26; p=0.15).Conclusions: A small percentage (1.5%) of N9831 patients did not meet ASCO/CAP 2007 guidelines when applied retrospectively. Trastuzumab effect appeared similar for HER2+ patients regardless of ASCO/CAP or FDA-approved guidelines. Additional DFS analyses by IHC/FISH subgroups will be presented. We gratefully acknowledge support from the Breast Cancer Research Foundation, Genentech, and NIH CA25224 for this study. Citation Information: Cancer Res 2009;69(24 Suppl):Abstract nr 701.
Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia
Chen, Christine I. , Bergsagel, P. Leif , Paul, Harminder, Xu, Wei , Lau, Anthea , Dave, Nimisha, Kukreti, Vishal , Wei, Ellen, Leung-Hagesteijn, Chungyee, Li, Zhihua , Brandwein, Joseph , Pantoja, Mariela, Johnston, James B. , Gibson, Spencer B. , Hernandez, Tiffany, Spaner, David , Trudel, Suzanne , Bergsagel, P. Leif

Mayo Clinic

Journal of Clinical Oncology | December 29, 2010 | Volume: 29 | Issue: 9 | Pages: 1175-1181

10.1200/jco.2010.29.8133 | PMID 21189385 Get It

PurposeLenalidomide is an oral immunomodulatory drug with multiple effects on the immune system and tumor cell microenvironment leading to inhibition of malignant cell growth. Based on encouraging reports of lenalidomide in relapsed and refractory chronic lymphocytic leukemia (CLL), we investigated the first-line use of single-agent lenalidomide in CLL.Patients and MethodsUsing a starting dose of lenalidomide 10 mg/d for 21 days of a 28-day cycle and weekly 5-mg dose escalations to a target of 25 mg, we encountered severe toxicities (tumor lysis, fatal sepsis) in the first two patients enrolled. The study was halted and the protocol amended to a more conservative regimen: starting dose of lenalidomide 2.5 mg with monthly escalations to a target dose of 10 mg, and extended tumor lysis prophylaxis and monitoring. Gene expression profiles from patient samples before and after 7 days of lenalidomide were performed.ResultsTwenty-five patients were enrolled on the amended protocol. No further tumor lysis events were reported. Tumor flare was common (88%) but mild. Grade 3 to 4 neutropenia occurred in 72% of patients, with only five episodes of febrile neutropenia. The overall response rate was 56% (no complete responses). Although rapid peripheral lymphocyte reductions were observed, rebound lymphocytoses during the week off-therapy were common. Lenalidomide-induced molecular changes enriched for cytoskeletal and immune-related genes were identified.ConclusionLenalidomide is clinically active as first-line CLL therapy and is well-tolerated if a conservative approach with slow dose escalation is used. A lenalidomide-induced molecular signature provides insights into its immunomodulatory mechanisms of action in CLL.
The Aging Heart, Myocardial Fibrosis, and its Relationship to Circulating C-Type Natriuretic Peptide
Sangaralingham, S. Jeson , Huntley, Brenda K., Martín, Fernando L., Bellavia, Diego , Ichiki, Tomoko , Harders, Gerald E., Chen, Horng H. , Burnett, John C. , Sangaralingham, S. Jeson , McKie, Paul M.

Mayo Clinic

Hypertension | December 28, 2010 | Volume: 57 | Issue: 2 | Pages: 201-207

10.1161/hypertensionaha.110.160796 | PMID 21189408 Get It

Myocardial aging is characterized by left ventricular (LV) fibrosis leading to diastolic and systolic dysfunction. Studies have established the potent antifibrotic and antiproliferative properties of C-type natriuretic peptide (CNP); however, the relationship between circulating CNP, LV fibrosis, and associated changes in LV function with natural aging are undefined. Accordingly, we characterized the relationship of plasma CNP with LV fibrosis and function in 2-, 11-, and 20-month–old male Fischer rats. Further in vitro, we established the antiproliferative actions of CNP and the participation of the clearance receptor using adult human cardiac fibroblasts. Here we establish for the first time that a progressive decline in circulating CNP characterizes natural aging and is strongly associated with a reciprocal increase in LV fibrosis that precedes impairment of diastolic and systolic function. Additionally, we demonstrate in cultured adult human cardiac fibroblasts that the direct antiproliferative actions of high-dose CNP may involve a non-cGMP pathway via the clearance receptor. Together, these studies provide new insights into myocardial aging and the relationship to the antifibrotic and antiproliferative peptide CNP.
Cross-linking Characteristics and Mechanical Properties of an Injectable Biomaterial Composed of Polypropylene Fumarate and Polycaprolactone Co-polymer
Yan, Jun, Li, Jianmin , Runge, M. Brett, Dadsetan, Mahrokh, Chen, Qingshan , Lu, Lichun , Yaszemski, Michael J.

Mayo Clinic

Journal of Biomaterials Science, Polymer Edition | December 10, 2010 | Volume: 22 | Issue: 4-6 | Pages: 489-504

10.1163/092050610x487765 | PMID 20566042 Get It